 | Fiscal Note3rd Sub. H.B. 389 (Cherry) 2026 General Session Cannabis Amendments by Dailey-Provost, Jennifer |  |
| Ongoing | One-time | Total | |
|---|---|---|---|
| Net GF/ITF/USF (rev.-exp.) | $0 | $0 | $0 |
| Revenues | FY2026 | FY2027 | FY2028 |
| Dedicated Credits Revenue | $0 | $43,400 | $43,400 |
| Dedicated Credits Revenue, One-time | $0 | $35,000 | $0 |
| Qualified Production Enterprise Fund | $0 | $2,413,900 | $2,413,900 |
| Total Revenues | $0 | $2,492,300 | $2,457,300 |
Enactment of this legislation could increase revenue to the Qualified Patient Enterprise Fund by $2,413,900 ongoing beginning in FY 2027 from authorizing the collection of a uniform transaction fee on medical cannabis sales. Enactment of this legislation could also increase Dedicated Credit revenue to the Attorney General's Office by $35,000 one-time and by $43,400 ongoing beginning in FY 2027 to accommodate moving programs across agencies and to support the expanded responsibilities of the Specialized Product Authority Licensing Board.
| Expenditures | FY2026 | FY2027 | FY2028 |
| Dedicated Credits Revenue | $0 | $43,400 | $43,400 |
| Dedicated Credits Revenue, One-time | $0 | $35,000 | $0 |
| Qualified Production Enterprise Fund | $0 | $2,413,900 | $2,413,900 |
| Total Expenditures | $0 | $2,492,300 | $2,457,300 |
Enactment of this legislation could increase expenditures by the Department of Agriculture and Food by $2,413,900 annually beginning in FY 2027 from the Qualified Production Enterprise Fund for staff, legal services, and enforcement in the specialized product division. Enactment could also shift Qualified Patient Enterprise Fund expenditures by $1,646,400 one-time in FY 2026 and $4,599,200 ongoing beginning in FY 2027 from the Department of Health and Human Services to the Department of Agriculture and Food (UDAF) from moving the medical cannabis program responsibilities in Title 26B to UDAF. Enactment of this legislation could also increase Dedicated Credit expenditures by the Attorney General's Office by $35,000 one-time and by $43,400 ongoing beginning in FY 2027 to accommodate moving programs across agencies and to support the expanded responsibilities of the Specialized Product Authority Licensing Board
| FY2026 | FY2027 | FY2028 | |
| Net All Funds (rev-exp) | $0 | $0 | $0 |
Enactment of this legislation likely will not result in direct, measurable costs for local governments.
Enactment of this legislation could cost medical cannabis patients $2,413,900 ongoing beginning in FY 2027 from paying an additional uniform transaction fee on medical cannabis purchases.
Enactment of this legislation likely will not change the regulatory burden for Utah residents or businesses.
This bill does not create a new program or significantly expand an existing program.